Document is current
Any future updates will be listed below
-
Authors
Vadodaria, Krishna C. https://orcid.org/0000-0002-3455-0209
Serrats, Jordi
Brubaker, William
Kangas, Brian D. https://orcid.org/0000-0002-4597-9801
Pizzagalli, Diego A. https://orcid.org/0000-0002-7772-1143
Garvey, Dave S.
Sudarsan, Vikram
Vanover, Kimberly E.
-
Funding
Funding for this research was provided by:
Engrail Therapeutics
- License Information
-
More Information
Article History
Received: 13 July 2025
Revised: 3 October 2025
Accepted: 10 November 2025
First Online: 7 December 2025
Competing interests
: KCV, JS, WB, KEV and VS are/were employees of Engrail Therapeutics at the time of this research and may own stock and/or stock options in the company. Over the past 3 years, BDK has received sponsored research agreements from BlackThorn Therapeutics, Compass Pathways, Delix Therapeutics, Engrail Therapeutics, Neurocrine Biosciences, and Takeda Pharmaceuticals. Over the past 3 years, DAP has received consulting fees from Abbvie, Arrowhead Pharmaceuticals, Boehringer Ingelheim, Compass Pathways, Engrail Therapeutics, Neumora Therapeutics, Neurocrine Biosciences, Neuroscience Software, Otsuka Pharmaceuticals, Sage Therapeutics, and Takeda Pharmaceuticals; honoraria from the Psychonomic Society and the American Psychological Association (for editorial work) and Alkermes, and research funding from the Bird Foundation, Brain and Behavior Research Foundation, DARPA, Millennium Pharmaceuticals, and the National Institute of Mental Health. In addition, he has received stock options from Ceretype Neuromedicine, Compass Pathways, Engrail Therapeutics, Neumora Therapeutics, and Neuroscience Software. DSG is/was a paid consultant for Engrail Therapeutics at the time of this research. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.
